Skip to main content Accessibility help
×
Home

Aripiprazole treatment effects on metabolic syndrome parameters in schizophrenia patients: Preliminary results

  • M. Said (a1) (a2), A.H. Sulaiman (a3) and M.H. Habil (a3)

Abstract

Introduction

Metabolic abnormalities have historically been associated with illness such as schizophrenia. However, many studies found aripiprazole has a safer metabolic profile and metabolic neutral for schizophrenic patient.

Objective

This is a prospective 24 weeks follow-up study. The primary objective of this study was to investigate the improvements in metabolic syndrome parameters observed in patients who were switched from other antipsychotics.

Methods

Patients with schizophrenia treated with antipsychotic who were having abnormal metabolic parameters were switched to aripiprazole. They were analyzed to quantify clinically significant changes in metabolic parameters. At baseline, weight, waist circumference, blood pressure and fasting blood sugar were assessed. Fasting lipid profile was taken for total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides at baseline. The same assessments were repeated at 4-weeks, 12-week and 24-week. Paired t-test and last observation carried forward (LOCF) were used for the statistical analysis.

Preliminary results for those who completed 12 weeks follow up were presented.

Results

46 schizophrenic patients with 26 (56.5%) male and 20 (43.5%) female have completed the 12 weeks follow up. There was statistically significant reduction in mean weight (73.3 ± 19.2 kg) to (71.2 ± 20.5 kg), mean BMI (27.1 ± 5.4) to (26.2 ± 6.0), mean waist circumference for male (96.2 ± 14.1 cm) to (92.9 ± 17.9), mean triglycerices (1.86 ± 0.83 mmol) to (1.59 ± 0.54 mmol).

Conclusion

In short-term, switching to aripiprazole treatment resulted in clinically significant improvements in weight, BMI, waist circumference in male, and triglycerices in at-risk patients.

Copyright

Aripiprazole treatment effects on metabolic syndrome parameters in schizophrenia patients: Preliminary results

  • M. Said (a1) (a2), A.H. Sulaiman (a3) and M.H. Habil (a3)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

Aripiprazole treatment effects on metabolic syndrome parameters in schizophrenia patients: Preliminary results

  • M. Said (a1) (a2), A.H. Sulaiman (a3) and M.H. Habil (a3)
Submit a response

Comments

No Comments have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *